Skip to main content

Table 1 Patient characteristics (n = 391)

From: Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data

Variable

 

Demographic data

 Female, n (%)

148 (38)

 Age, years

67 ± 14

 Height, cm

161 ± 11

 Body weight, kg

57 ± 15

 Body mass index, kg/m2

22 ± 4

LVEF, %

39 ± 14

NYHA class II/III/IV, n

291/67/33

Underlying heart disease

 Coronary artery disease, n (%)

59 (15)

 Nonischaemic cardiomyopathies, n (%)

109 (28)

 Valvular disease, n (%)

57 (15)

 Hypertensive heart disease, n (%)

27 (7)

 Congenital heart disease, n (%)

26 (7)

 Others, n (%)

113 (29)

Atrial fibrillation

 Permanent/persistent, n (%)

312 (80)

 Paroxysmal, n (%)

76 (20)

ICD/pacemaker, n (%)

53 (14)

Clinical laboratory data

 Serum creatinine, mg/dL

0.94 [0.75–1.15]

 CLCR, mL/min

56.5 [40.7–75.6]

 eGFR, mL/min/1.73m2

58.1 [44.7–71.0]

Daily dose of digoxin

 0.25 mg, n (%)

51 (13)

 0.125 mg, n (%)

287 (73)

 0.0625 mg, n (%)

39 (10)

 Other doses, n (%)

14 (4)

Duration of digoxin treatment, days

350 [60–1340]

Concurrent medications of interest

 Amiodarone, n (%)

63 (16)

 Diltiazem, n (%)

33 (8)

 Verapamil, n (%)

23 (6)

  1. Values are n (%) or means ± SD or median [interquartile range]
  2. CLCR creatinine clearance, eGFR estimated glomerular filtration rate, ICD implantable cardioverter-defibrillator, LVEF left ventricular ejection fraction, NYHA New York Heart Association